1.	Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: 20050113, NCT00243685
2.	Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: WIRB 20060042, NCT00443196
3.	Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 110655, AGO-OVAR16, NCT00866697
4.	Phase III Randomized Study of Bevacizumab in Combination With Intravenous Versus Intraperitoneal Chemotherapy in Patients With Stage II or III Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Carcinoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: GOG-0252, GOG -0252, NCT00951496
5.	Phase I/II Study of Pentostatin and Donor Lymphocyte Infusion in Preventing Graft Rejection in Cancer Patients With Low or Falling Donor T-Cell Chimerism After Nonmyeloablative Allogeneic Stem Cell Transplantation Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 75 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
6.	Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: Å6-003, NCT00083928
7.	DOXIL for Consolidation Therapy in Ovarian Cancer. Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SEGO_DOXIL_CONS2005, NCT00248248
8.	Phase II Randomized Study of Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UMN-2005NT018, UMN-0506M70866, UMN-MT2005-06, NOVARTIS-CZOL446EUS29, NCT00321932
9.	Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor Phase: Phase II Type: Treatment Status: Active Age: 50 to 70 Sponsor: Other Protocol IDs: RMBMT-124-A, NCT00304720
10.	Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: IP-REM-AC-02-US, NCT00326885
11.	Phase II Pilot Study of Irradiated Allogeneic Related Donor Lymphocyte Infusion in Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: NCI Protocol IDs: CINJ-3330, NCT00161187
12.	Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor Phase: Phase II Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 2006-0873, NCT00523809
13.	Phase II Study of Conditioning Regimen Comprising Anti-thymocyte Globulin, Clofarabine, and Rituximab in Patients With Primary or Secondary Graft Failure After Hematopoietic Stem Cell Transplantation Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: NCI Protocol IDs: UMN-2007LS072, UMN-2007LS072, UMN-MT2007-07, NCT00617929
14.	Platinum Resistant Ovarian Cancer Evaluation of Doxil and EC145 Combination Therapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EC-FV-04, NCT00722592
15.	A Study of GDC-0449 (Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SHH4489g, NCT00739661
16.	Trial Of Double Umbilical Cord Blood Transplantation Phase: Phase II Type: Treatment Status: Active Age: 65 and under Sponsor: Other Protocol IDs: umcc 2007.137, HUM00017515, NCT00763490
17.	Efficacy Study of Gleevec and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06-226, CSTI57BUS224, NCT00840450
18.	Efficacy and Safety and Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06-948, Genentech AVF3910s, NCT00846612
19.	Phase I Study of Adjuvant Paclitaxel And Bevacizumab in Combination With Intraperitoneal Carboplatin in Patients With Stage II-IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Who Had Initial Debulking Surgery Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: GOG-9917, NCT00079430
20.	Phase I Study of Intraperitoneal (IP) Carboplatin, IP Paclitaxel , and Intravenous (IV) Paclitaxel With or Without Bevacizumab OR IV Docetaxel, IP Paclitaxel, and IP Carboplatin in Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: GOG-9916, NCT00085358
21.	Phase I Study Using Sunitinib Plus Radiation Therapy for Cancer Patients Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06C.549, NCT00437372
22.	A Phase I Study of Intraperitoneal Hyperthermic Docetaxel Phase: Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: BCC-GYN-07-001, NCT00474669
23.	Phase I Study of Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes in Patients Undergoing Mismatched-Related or Phenotypically Similar Unrelated Donor Marrow Transplantation Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: BCM-H-6676, H 6676, BCM-ETNA, NCT00608309
24.	Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 00005124, NCT00586690
25.	Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 00005123, NCT00586703